Innate Pharma (IPH) Investor Update summary

Strategic and Clinical Development Update

• Focused on three priority assets: lacutamab, IPH4502, and monalizumab, with streamlined R&D and a 30% organizational reduction to align with new strategy.

• Lacutamab, a first-in-class anti-KIR3DL2 antibody, is advancing toward accelerated approval in Sézary syndrome, with confirmatory Phase III protocols for both SS and MF submitted to the FDA.

• Monalizumab, partnered with AstraZeneca, is in a Phase III study (PACIFIC-9) with data expected in 2026 and significant milestone and royalty potential.

• IPH4502, a Nectin-4 targeted ADC, is in Phase I with early clinical activity and data expected by early next year.

Clinical Efficacy, Safety, and Unmet Needs in CTCL

• CTCL, especially Sézary syndrome and advanced mycosis fungoides, has poor prognosis and significant unmet need for effective, well-tolerated systemic therapies.

• TELLOMAK Phase II data showed lacutamab delivers rapid, durable responses and significant quality of life improvements in SS and MF, regardless of KIR3DL2 expression.

• In SS post-mogamulizumab, lacutamab achieved a global ORR of 42.9%, median PFS of 8.3 months, and median DoR of 25.6 months.

• In MF, lacutamab induced deep responses with a global clinical benefit rate of 86% and median PFS of 10.2 months.

• Safety profile is favorable, with low rates of serious adverse events and treatment discontinuation, supporting long-term use.

Regulatory Progress and Milestones

• Regulatory designations include FDA Breakthrough Therapy, Orphan Drug, Fast Track, and EMA PRIME, enabling accelerated approval and market exclusivity.

• No new data required for accelerated approval in SS; Phase III design includes two cohorts (SS and MF) with primary endpoint of progression-free survival.

• Key milestones include US accelerated approval in 2027 for SS and potential US approval for MF in 2029.

• Upcoming catalysts: Phase I data for IPH4502, PACIFIC-9 readout for monalizumab, and BLA submissions for lacutamab and monalizumab.